Hostname: page-component-54dcc4c588-2bdfx Total loading time: 0 Render date: 2025-09-26T21:06:34.952Z Has data issue: false hasContentIssue false
  • English
  • Français

Influence of polygenic risk for schizophrenia and cannabis use on cognition

Published online by Cambridge University Press:  26 August 2025

A. Flores ,
G. Cano ,
I. Zorrilla ,
S. Amoretti ,
E. Vieta ,
L. Pina-Camacho ,
A. M. Sánchez-Torres ,
D. Bergé ,
S. Mas  and
A. González-Pinto
A. Flores*
Affiliation:
Hospital Santiago Apóstol BIOARABA
G. Cano
Affiliation:
BIOARABA CIBERSAM, Vitoria-Gasteiz
I. Zorrilla
Affiliation:
Hospital Santiago Apóstol BIOARABA
S. Amoretti
Affiliation:
Hospital Clínic, Barcelona
E. Vieta
Affiliation:
Hospital Clínic, Barcelona
L. Pina-Camacho
Affiliation:
Hospital Gregorio Marañón, Madrid
A. M. Sánchez-Torres
Affiliation:
Complejo Hospitalario Navarra, Pamplona
D. Bergé
Affiliation:
Hospital del Mar
S. Mas
Affiliation:
CIBERSAM, Barcelona, Spain
A. González-Pinto
Affiliation:
Hospital Santiago Apóstol BIOARABA CIBERSAM, Vitoria-Gasteiz
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

There is increasing scientific evidence linking the influence of cannabis on the onset of a first psychotic episode (FEP). However, this association may not always be one-way when studying the relationship between cannabis use and cognition.

The role of polygenic risk score for Schizophrenia (PRS-SZ) and lifetime cannabis initiation (PRSCI) and cannabis use disorder (PRSCUD) use remains unresolved. For this reason, a study was carried out to clarify how these factors are related to each other.

Objectives

To study the interaction between genetic risk and environmental factors

To analyze the relationship between polygenic risk scores and clinical features

To determine the impact of cannabis use on cognitive performance

Methods

A neuropsychological study was carried out on a sample of 138 cannabis users, divided into cases and controls according to the existence of a FEP. This assessment included domains of processing speed, verbal memory, attention, working memory, executive function, social cognition, and determination of premorbid IQ, using validated tests.

Three GWAS summary statistics were used to calculate individual PRS conferring risk for SZ, CI and CUD. PRS were constructed using PRS-CS.

The results obtained were then statistically correlated with the polygenic risk score for schizophrenia, cannabis use disorder, and lifetime cannabis use, respectively.

Results

The patient group presented worse processing speed as the risk for schizophrenia increased. In the case of PRS-CU, an opposite effect was evident. For verbal memory, a higher PRS-CUD was associated with poorer performance. Cannabis consumers with lifetime risk presented better executive function than consumers with lower genetic risk.

Conclusions

The relationship between PRS for Schizophrenia and cannabis use remains uncertain. However, different clinical profiles can be determined thanks to the cognitive assessment.

Disclosure of Interest

None Declared

Information

Type
Abstract
Information
European Psychiatry , Volume 68 , Special Issue S1: Abstracts of the 33rd European Congress of Psychiatry , April 2025 , pp. S587 - S588
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2025. Published by Cambridge University Press on behalf of European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.